Koselugo

Active Ingredient(s): Selumetinib Sulfate
FDA Approved: * April 10, 2020
Pharm Company: * ASTRAZENECA PHARMS
Category: Genetic Disorders

Selumetinib (INN),[6] sold under the brand name Koselugo, is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves.[7] It is taken by mouth.[3] Common side effects include headache, abdominal pain and other problems of the gastrointestinal tract, fatigue, muscle pain, as well as dry skin and other skin problems.&#... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Koselugo 10 mg Oral Capsule
NDC: 0310-0610
Labeler:
Astrazeneca Pharmaceuticals Lp
Koselugo 25 mg Oral Capsule
NDC: 0310-0625
Labeler:
Astrazeneca Pharmaceuticals Lp